Related Experiment Video
Updated: Jan 29, 2026
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
1.5K
Diabetic cardiomyopathy: factual or factoid?
Thiago Quinaglia1, Daniela C Oliveira1, José Roberto Matos-Souza1
1Subject of Cardiology, Faculty of Medical Sciences - State University of Campinas (Unicamp), Campinas, SP, Brasil.
Revista Da Associacao Medica Brasileira (1992)
|February 14, 2019
Summary
Diabetic Cardiomyopathy (CMPDM) remains debated, but evidence links diabetes mellitus (DM) to heart failure (HF). New drugs show promise for preventing and treating HF in diabetic patients.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Diseases
Background:
- Diabetic Cardiomyopathy (CMPDM) lacks a definitive consensus on its existence due to complex pathophysiology linking diabetes mellitus (DM) and heart failure (HF).
- Epidemiological data strongly supports a connection between DM and HF, highlighting the need for understanding the underlying myocardial disease mechanisms.
Purpose of the Study:
- To review the epidemiology and pathogenic mechanisms of Diabetic Cardiomyopathy (CMPDM).
- To present the main cardiac phenotypes associated with CMPDM, including heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
- To discuss the implications for therapeutic management of CMPDM in patients with DM.
Main Methods:
- Literature review focusing on epidemiological evidence, pathogenic mechanisms, cardiac phenotypes, and therapeutic strategies for Diabetic Cardiomyopathy.
- Analysis of recent clinical trial data on glucose-lowering drugs, particularly sodium-glucose transporter 2 inhibitors (SGLT2i), in patients with DM and HF.
Main Results:
- Undisputed epidemiological evidence links DM to HF, despite ongoing debate on CMPDM's distinct existence.
- Recent trials with SGLT2 inhibitors demonstrate significant benefits in preventing and treating HF in patients with DM.
- CMPDM presents with various cardiac phenotypes, including HFpEF and HFrEF.
Conclusions:
- Understanding Diabetic Cardiomyopathy (CMPDM) is crucial, with growing evidence supporting its link to diabetes mellitus (DM) and heart failure (HF).
- Sodium-glucose transporter 2 inhibitors represent a promising therapeutic avenue for managing cardiac complications in diabetic patients.
- Further research into CMPDM's mechanisms and phenotypes is essential for optimizing patient care.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
557
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
557
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
483
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
483
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
526
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
526
01:29Cardiomyopathy V: Interprofessional Care
439
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
439
01:25Cardiomyopathy I: Introduction and Classification
599
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
599
01:29Cardiomyopathy VI: Nursing Management
354
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
354